Publication
Horizon Scanning: Investigations and Enforcement
In this horizon scan, we focus on key developments affecting companies operating in the UK, including in light of the recent change in UK government.
Global | Publication | November 2016
The European Medicines Agency (EMA) issued guidance on the implementation of its Policy 0070 on the publication of clinical data for medicines, including with respect to anonymization of clinical reports for publication. As background, please see our previous briefing on the EMA’s new approach to transparency of clinical studies here. As of October 2016, all drug manufacturers that are making a marketing authorization application under the centralized procedure in Europe will be subject to the new guidance.1
Similar to the US Food & Drug Administration, the EMA ensures that medicines sold in the EU markets under a centralized marketing authorization are safe and effective. EMA Policy 0070 provides for the proactive publication by the EMA of clinical data from clinical reports submitted to it. The clinical reports will be made available to the public for general information, academic use and other non-commercial purposes. One of the underlying concerns in this shift toward transparency is the privacy of clinical study subjects.
Balancing subject privacy and transparency presents drug manufacturers with a difficult task—how to increase transparency of clinical studies while also attenuating the risk of subject reidentification. In its guidance, the EMA discusses three approaches to anonymization of clinical reports:
These anonymization techniques can be used separately or in combination. One industry commenter suggests that manufacturers should focus on anonymizing patient-level data to ensure that downstream uses of that data are secure, including use in clinical reports, and maintains that this method is superior to ad hoc masking of the data, which may be more prone to error. However, the EMA’s guidance does not mandate use of any specific methodology.
Whilst the first phase of implementing EMA Policy 0070 has been focused on publication of clinical data which relates to clinical reports only, the second phase will involve the EMA finding the most appropriate way to make available individual patient data in compliance with privacy and data protection laws. Pharmaceutical companies should anticipate more calls for transparency in clinical studies. At the same time, organizations should continue to be mindful of best practices when it comes to anonymizing and securing data. Future compliance may require organizations to anonymize patient-level data at an earlier stage in the clinical trial process. In anticipation of those changes, companies should proactively develop policies and procedures for implementing long-term solutions to anonymization.
Applications which must be submitted through this procedure, and not national procedures, are: certain biotechnology products; advanced therapy medicinal products; new active substances with certain therapeutic substances (such as cancer); and orphan medicines.
These techniques are consistent with the Article 29 Working Party’s Opinion 05/2014 (WP216) on Anonymisation Techniques.
Publication
In this horizon scan, we focus on key developments affecting companies operating in the UK, including in light of the recent change in UK government.
Publication
As you begin planning for the upcoming financial year, it is likely that legal operations projects are on your radar. However, securing the necessary budget can be challenging. Our roundtable on October 1, ‘Preparing for FY2025 - Building a compelling business case’, will help you create compelling business cases for your legal initiatives.
Publication
This briefing is an updated version of our briefing first published in December 2017 and sets out some practical pointers for employers who wish to make changes to a pension scheme which may fall within the statutory definition of a “listed change”.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023